Dabigatran in atrial fibrillation

4th April 2012 by Louise Hudman

This guideline lays out the criteria for the use of Dabigatran, a thrombin inhibitor.

It can be considered as an alternative to warfarin in non-valvular AF if at least one of the following applies:

  • Previous CVA / TIA / systemic embolism
  • LV ejection fraction < 40%
  • Heart Failure NYHA II or above
  • ≥ 75
  • ≥ 65 + DM or coronary artery disease or hypertension

It is much more expensive than warfarin, though at higher doses is more effective at reducing stroke. Its major benefits are in not having so many food and drug interactions and not needing monitoring. We will need to wait to see how this will be used locally.

Read more

No credit card details needed – it takes two minutes.

Join free trial


Already a member? Login to view this content.


"I am all set up and running on LocumDeck. I'm very impressed by how efficient and smooth it seems."

Dr Paula Zukowski, GP, Norwich

Dr Paula Zukowski, GP, Norwich

See the full list of features within our NASGP membership plans